Citation Impact
Citing Papers
Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours – a retrospective long-term follow-up study
2003
Cancer treatment and survivorship statistics, 2022
2022 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Testicular Germ-Cell Cancer
1997 Standout
Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
2013
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
2009
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
2005
Heating the patient: a promising approach?
2002 Standout
Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG
2013
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Current views on the pathogenesis of testicular germ cell tumours and perspectives for future research: Highlights of the 5th Copenhagen Workshop on Carcinoma in situ and Cancer of the Testis
2003
The cellular and molecular basis of hyperthermia
2002 Standout
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
“Onco-tese”: testicular sperm extraction in azoospermic cancer patients before chemotherapy—new guidelines?
2003
Testicular sperm extraction (TESE) and ICSI in patients with permanent azoospermia after chemotherapy
2003
Intravesical gemcitabine: an update of clinical results
2006
Bropirimine in Bladder Cancer: Clinical Studies
1993
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
2005 Standout
Fertility considerations in men with testicular cancer
2020
Prognostic Factors in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
2007
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Testicular germ-cell tumours in a broader perspective
2005 Standout
A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C
2007
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
Angiogenesis in life, disease and medicine
2005 StandoutNature
Systematic Review of Adrenalectomy and Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma
2013
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancer
1998
EAU Guidelines on Prostate Cancer
2007 Standout
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
A Pretreatment Table for the Prediction of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer
2006
The Microvascular System of the Striate and Extrastriate Visual Cortex of the Macaque
2008
An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate Cancer
2007
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
What we can do and what we cannot do with fMRI
2008 StandoutNature
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Consensus Statement on Management of Intersex Disorders
2006 Standout
Macrophage plasticity and polarization: in vivo veritas
2012 Standout
Regulation of Vascularization by Hypoxia‐Inducible Factor 1
2009 StandoutNobel
The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
2003
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 Standout
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
2003
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Keyhole limpet hemocyanin (KLH): a biomedical review
1999
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancer
2010
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Laser Doppler Flowmetric Determination of Ureteral Blood Flow after Ureteral Access Sheath Placement
2002
HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL
2005
Toll-Like Receptors
2003 Standout
Clinical practice guidelines for antimicrobial prophylaxis in surgery
2013 Standout
Copper Active Sites in Biology
2014 Standout
Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response
2006
Marine natural products
2015 Standout
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Bladder Cancer
2020 Standout
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
2006
COMPLIANCE OF CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOR PATIENTS WITH SURVEILLANCE
1998
Prospective Evaluation and Classification of Ureteral Wall Injuries Resulting from Insertion of a Ureteral Access Sheath During Retrograde Intrarenal Surgery
2012 Standout
Combination therapy in combating cancer
2017 Standout
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events
2008
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
2002 Standout
Hyperthermia for the treatment of patients with malignant germ cell tumors
1998
PROPHYLATIC ANTIBIOTIC USE IN TRANSURETHRAL PROSTATIC RESECTION: A META-ANALYSIS
2002
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Social Support and Patient Adherence to Medical Treatment: A Meta-Analysis.
2004 Standout
Carcinoma in situ in the Testis
2000
Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold
2022 StandoutNobel
Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice.
2002
Cryo-negative staining
1998 StandoutNobel
Keyhole limpet haemocyanin (KLH): Purification of intact KLH1 through selective dissociation of KLH2
1995
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
2007
Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials
2002 Standout
Cancer de la prostate
2007
Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer
1995
INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL
2001
Works of W. Höltl being referenced
Testis‐preserving surgery in bilateral testicular germ cell tumours
1997
Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM)
2000
Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
1996
Impact of the Use of Bowel for Urinary Diversion on Perioperative Complications and 90-Day Mortality in Patients Aged 75 Years or Older
2015
Complete Androgen Deprivation prior to Radical Prostatectomy in Patients with Stage T(3) Cancer of the Prostate
1991
THE ABLATIVE EFFECT OF QUARTER DOSE BACILLUS CALMETTE-GUERIN ON A PAPILLARY MARKER LESION OF THE BLADDER
2001
Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial.
1990
Adrenalectomy — still a must in radical renal surgery?
1996
MANAGEMENT OF LOCALLY ADVANCED PROSTATE CANCER: A EUROPEAN CONSENSUS
2003
ORGAN SPARING SURGERY FOR MALIGNANT GERM CELL TUMOR OF THE TESTIS
2001
Does Isoniazid Reduce Side Effects of Intravesical Bacillus Calmette-Guerin Therapy in Superficial Bladder Cancer? Interim Results of European Organization for Research and Treatment of Cancer Protocol 30911
1997
Recurrent Superficial Transitional Cell Carcinoma of the Bladder: Adjuvant Topical Chemotherapy Versus Immunotherapy. A Prospective Randomized Trial
1990
[Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
1994
A PHASE II STUDY OF THE ABLATIVE EFFECT OF QUARTER DOSE BCG ON A PAPILLARY MARKER LESION OF THE BLADDER
1999
Low Dose Carboplatin Combined With Angiostatic Agents Prevents Metastasis in Human Testicular Germ Cell Tumor Xenografts
2003
The microvasculature of the guinea pig ureter. A scanning electron microscopic investigation.
1990
Single-Dose Antibiotic Prophylaxis in Transurethral Resection of the Prostate: A Prospective Randomized Trial
1999
EFFICIENT CARBOPLATIN SINGLE THERAPY IN A MOUSE MODEL OF HUMAN TESTICULAR NONSEMINOMATOUS GERM CELL TUMOR
2002